The diagnostic kit developed by CCERCI’s researchers was patented at the United States Patent Office.
The diagnostic kit developed at Nanosensor Bioplatforms Laboratory of CCERCI by Dr. Hamed Golmohammadi, Dr. Seyyed Hamid Ahmadi, and Raziyeh Sadat Tabatabaee was patented at the United States Patent Office (Measurement of bilirubin concentration in blood samples, US Patent App. 16/686, 262, 2020).
One of the concerns of parents in the first days of their baby’s birth is the baby’s risk of jaundice/hyperbilirubinemia. This is because more than 60% of babies are born with jaundice that, if not timely diagnosed and subsequently treated, can lead to serious damage to their health.
The patented smartphone-based diagnostic kit, as an easy-to-use, cost-effective (∼0.01 Euro per test), portable and novel assay kit, can be potentially exploited for sensitive, specific, rapid, and easy bilirubin detection and jaundice diagnosis at the point of care and in routine clinical laboratories as well.
Print 
Send to Friend